We are live on
!
Find out more
CM
Caption Management Portfolio holdings
AUM
$17.1B
1-Year Est. Return
70.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.28%
1 Year Est. Return
+70.99%
3 Year Est. Return
+176.06%
5 Year Est. Return
+263.89%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$172M
(+9.5%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
7.83%
Top 10 Holdings %
Top 10 Hldgs %
16.27%
Holding
935
New
395
Increased
92
Reduced
99
Closed
294
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$8.42M |
| 2 |
Marathon Petroleum
MPC
|
+$5.47M |
| 3 |
Liberty Global Class C
LBTYK
|
+$5.39M |
| 4 |
O'Reilly Automotive
ORLY
|
+$5.32M |
| 5 |
Crocs
CROX
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$12.6M |
| 2 |
Tapestry
TPR
|
+$12M |
| 3 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$8.32M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$6.96M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$6.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.95% |
| 2 | Consumer Discretionary | 2.51% |
| 3 | Technology | 1.96% |
| 4 | Energy | 1.43% |
| 5 | Communication Services | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
CALL
Team
TISI
$79.5M
| $55K | ﹤0.01% |
+360
| New | +$58.1K |
|
|
NPTN
627
DELISTED
NEOPHOTONICS CORP
NPTN
| $53K | ﹤0.01% |
+12,700
| New | +$67K |
|
628
PUT
ProPetro Holding
PUMP
$1.36B
| $51K | ﹤0.01% |
+2,500
| New | +$53.1K |
|
|
RESN
629
DELISTED
Resonant Inc.
RESN
| $50K | ﹤0.01% |
21,000
-79,000
| -79% | -$221K |
|
|
CPRX
630
DELISTED
Catalyst Pharmaceutical
CPRX
| $46K | ﹤0.01% |
+12,000
| New | +$51.8K |
|
631
Nutanix
NTNX
$16B
| $40K | ﹤0.01% |
1,500
-63,500
| -98% | -$2.21M |
|
|
INAP
632
PUT
DELISTED
Internap Corporation
INAP
| $23K | ﹤0.01% |
+7,500
| New | +$26.7K |
|
|
UXIN
633
Uxin Ltd
UXIN
$306M
| $20K | ﹤0.01% |
+91
| New | +$24K |
|
|
634
Team
TISI
$79.5M
| $17K | ﹤0.01% |
+110
| New | +$17.7K |
|
635
BioCryst Pharmaceuticals
BCRX
$2.28B
| $16K | ﹤0.01% |
4,400
-20,600
| -82% | -$124K |
|
|
DVAX
636
DELISTED
Dynavax Technologies
DVAX
| $16K | ﹤0.01% |
4,000
-3,200
| -44% | -$18.6K |
|
637
Ironwood Pharmaceuticals
IRWD
$696M
| $5K | ﹤0.01% |
400
-101,090
| -100% | -$1.13M |
|
638
Sea Limited
SE
$65.4B
| $3K | ﹤0.01% |
+100
| New | +$2.71K |
|
|
AMRS
639
DELISTED
Amyris Inc.
AMRS
| $2K | ﹤0.01% |
+700
| New | +$2.76K |
|
|
FTD
640
DELISTED
FTD Companies, Inc. Common Stock
FTD
| $1K | ﹤0.01% |
+50,000
| New | +$31.7K |
|
641
AbbVie
ABBV
$443B
| – | – |
-25,000
| Closed | -$1.96M |
|
|
642
PUT
AbbVie
ABBV
$443B
| – | – |
-65,000
| Closed | -$5.24M |
|
643
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
| – | – |
-35,000
| Closed | -$940K |
|
644
CALL
Aldeyra Therapeutics
ALDX
$92.9M
| – | – |
-54,000
| Closed | -$487K |
|
645
CALL
AnaptysBio
ANAB
$1.58B
| – | – |
-30,000
| Closed | -$2.19M |
|
|
646
PUT
AnaptysBio
ANAB
$1.58B
| – | – |
-30,000
| Closed | -$2.19M |
|
647
Apyx Medical
APYX
$173M
| – | – |
-10,000
| Closed | -$63K |
|
648
Aqua Metals
AQMS
$8.99M
| – | – |
-140
| Closed | -$85K |
|
649
CALL
Ashland
ASH
$3.33B
| – | – |
-25,000
| Closed | -$1.95M |
|
|
AVNS
650
CALL
DELISTED
Avanos Medical
AVNS
| – | – |
-20,000
| Closed | -$853K |
|
Similar funds
ASRS
PP
VMPIC
BCIM
BBA
FCM
AIMCA
Caption Management's Q2 2019 Portfolio in Review
As of Q2 2019, Caption Management held 935 positions worth $1.99B, up 9.5% from $1.81B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Caption Management deployed $156M of net new capital in Q2 2019, opening 395 new positions and adding to 92 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
By sector, the portfolio is most concentrated in Healthcare at 3% of assets, down from 3.9% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $12.6M trimmed.
- Caption Management's largest Q2 2019 buy was Spark Therapeutics, Inc. Common Stock: 78,000 shares worth $7.99M.
- Caption Management added most to Crocs in Q2 2019, an estimated $5.07M increase.
- Caption Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $12.6M.
- Caption Management fully exited iShares MSCI Saudi Arabia ETF in Q2 2019, selling an estimated $8.32M.
- Caption Management's ten largest holdings make up 16% of its $1.99B portfolio in Q2 2019.
- Caption Management opened 395 new positions and closed 294 in Q2 2019.
- Caption Management's portfolio value rose 9.5% quarter-over-quarter to $1.99B.
Based on Caption Management's 13F filing for Q2 2019, filed 13 Aug 2019.